IP Library Granted Patent US 9,644,195
Granted Patent B2
US 9,644,195 · App. 14/723,395 · Granted May 9, 2017

Compounds and methods for purification of serine proteases

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,644,195
App. No.
14/723,395
Granted
May 9, 2017
Kind
B2
Abstract

Disclosed herein are compounds, compositions, methods and kits for purifying a serine protease and serine proteases purified with the compounds, compositions and methods.

Claims (23)

1. A compound selected from:

or a salt thereof.

2. An affinity solid support selected from:

or a salt thereof,

wherein:

Y—Z is

Z is a solid support;

q is 3, 4 or 6; and

v is 1, 2, 3, 4, 5, 6 or 7.

3. The affinity solid support of claim 2 , wherein Z is an agarose resin.

4. A kit for purifying a serine protease comprising

(1) an affinity solid support of claim 2 , and

(2) an elution buffer comprising a competitive agent.

5. A kit for purifying a serine protease comprising a compound of claim 1 and a resin of the formula NC—O—Z or

wherein Z is a solid support.

6. The kit of claim 5 , wherein Z is an agarose resin.

7. A method for purifying a fXa derivative comprising

(1) adding a first composition comprising the fXa derivative to an affinity solid support of claim 2 or a salt thereof to form a second composition comprising the fXa derivative and the affinity solid support of claim 2 , and

(2) eluting the fXa derivative from the second composition with an elution buffer comprising a competitive agent,

wherein the fXa derivative is a polypeptide comprising the amino acid sequence of SEQ ID NO: 1, 2 or 4, or a polypeptide having at least about 80% sequence identity to SEQ ID NO: 1, 2 or 4 and further wherein the derivative is capable of binding to a fXa inhibitor and does not assemble into a prothrombinase complex.

8. The method of claim 7 , wherein the competitive agent is arginine and/or benzamidine, or a salt thereof.

9. The method of claim 7 , wherein the fXa derivative is a polypeptide comprising the amino acid sequence of SEQ ID NO: 2, or a polypeptide having at least about 90% sequence identity to SEQ ID NO: 2.

10. The method of claim 9 , wherein the polypeptide has at least about 95% sequence identity to SEQ ID NO: 2.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2022
From: ALEXION PHARMACEUTICALS, INC.
To: ALEXION PHARMA INTERNATIONAL OPERATIONS UNLIMITED COMPANY
Reel/Frame 060799/0729 →
CHANGE OF NAME Recorded Jan 7, 2021
From: PORTOLA PHARMACEUTICALS, INC.
To: PORTOLA PHARMACEUTICALS, LLC
Reel/Frame 054920/0739 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2021
From: PORTOLA PHARMACEUTICALS, LLC
To: ALEXION PHARMACEUTICALS, INC.
Reel/Frame 054921/0131 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2021
From: ALEXION PHARMA INTERNATIONAL OPERATIONS UNLIMITED COMPANY
To: ALEXION PHARMACEUTICALS, INC.
Reel/Frame 054922/0857 →
RELEASE OF SECURITY INTEREST Recorded Jul 2, 2020
From: HCR COLLATERAL MANAGEMENT, LLC
To: PORTOLA PHARMACEUTICALS, INC.
Reel/Frame 053120/0925 →
SECURITY INTEREST Recorded Mar 18, 2019
From: PORTOLA PHARMACEUTICALS, INC.
To: HCR COLLATERAL MANAGEMENT, LLC
Reel/Frame 048633/0673 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 28, 2015
From: PANDEY, ANJALI; ROSE, JACK W.
To: PORTOLA PHARMACEUTICALS, INC.
Reel/Frame 035730/0831 →